A DRUG used to ease jet lag could be used to tackle the “devastating” impact of painful side effects from cancer medicines, research suggests.
Scientists found the drug – known as melatonin – appeared to prevent pain caused by chemotherapy damage to nerves, blocking harmful effects on nerve health.
Experts say the findings help scientists understand more about ways to limit painful side effects of chemotherapy.
Scientists from the Universities of Edinburgh and Aberdeen focused on a common condition known as chemotherapy-induced neuropathic pain (CINP), which affects almost 70 per cent of patients undergoing chemotherapy.
The condition causes tingling and pain sensation to touch and to cold temperatures that can be severe enough to cause patients to limit their chemotherapy treatment.
The study with rats showed melatonin given prior to chemotherapy limited the damaging effect on nerve cells and the development of pain symptoms.
However it did not alleviate pain when CINP had already developed, suggesting its potential benefits could be as prevention rather than cure.
Melatonin treatment did not interfere with the beneficial anticancer effects of chemotherapy in human breast and ovarian cancer cells, researchers found.
Findings also showed that melatonin reduced damage caused by chemotherapy to vital parts of nerve cells known as mitochondria.
Experts say reducing harm to these cell energy centres could hold the key to preventing CINP.
Dr Carole Torsney from the University of Edinburgh’s Centre for Integrative Physiology, who co-led the study, said: “CINP can have a devastating impact on patients, and may limit chemotherapy doses, with potentially serious consequences.
“These findings are very exciting.”
Professor Helen Galley from the Institute of Medical Sciences at the University of Aberdeen, who co-led the study, said: “These results are promising, especially as melatonin treatment is known to be safe in other conditions.
“However, more work will need to be done before we know if melatonin will help prevent pain in cancer patients undergoing chemotherapy.”
CINP can have a severe impact on quality of life. Everyday activities, including fastening buttons or walking barefoot, can cause pain that can persist even after the cancer is cured, meaning that some patients are unable to return to work or able to carry out household tasks.
Experts said more work needs to be done to establish whether the findings can be developed into treatment.
Melatonin is a naturally occurring hormone that controls sleeping patterns, although synthetic versions can be produced in the laboratory.
It can be used to alleviate sleep disturbance but is not available in the UK without prescription.
Prof Lesley Colvin, pain specialist at the University of Edinburgh, said: “We are actively exploring an early-phase clinical study to see if these exciting laboratory findings might translate to direct benefit for patients undergoing chemotherapy.
“This is an area of real unmet need, where new therapies are urgently required.”
The study was published in the Journal of Pineal Research and was funded by the Association of Anaesthetists of Great Britain and Ireland, British Journal of Anaesthesia, the Royal College of Anaesthetists and the Melville Trust for the Care and Cure of Cancer.
ends
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here